Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease

NCT ID: NCT03998423

Last Updated: 2020-07-24

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-14
• Study Completion Date: 2020-07-14

Brief Summary

The goal of this study is to assess the safety and feasibility of an oral fecal microbiota transplant (FMT) intervention for Alzheimer's disease (AD).

Detailed Description

Studies suggests that microbes, including those derived from the gut, may play a role in the development or progression of AD. Gut microbiome composition among individuals with the Alzheimer's clinical syndrome is reduced in microbial diversity and shows compositional differences relative to control groups. Further, genera identified as more abundant in AD are associated with greater AD pathology while genera identified as less abundant in AD are associated with less AD pathology, as shown using CSF biomarkers.

The goal of this study is to assess the safety and feasibility of an oral fecal microbiota transplant (FMT) intervention.

• Primary Objective: To assess the safety and feasibility (recruitment, eligibility, enrollment, completion, and follow-up) of an oral FMT intervention in people with and without the Alzheimer's clinical syndrome.
• Secondary Objective: To demonstrate the effects of FMT on the composition and function of the gut microbiota. To collect preliminary data in order to estimate sample size and other parameters for a larger study.

Conditions

Alzheimer Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1 dose fecal microbiota transplant

This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.

Group Type: EXPERIMENTAL

Fecal Microbiota Transplant

Intervention Type: BIOLOGICAL

Double-encapsulated Fecal Microbiota Transplant Capsules

2 doses fecal microbiota transplant

This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.

Group Type: EXPERIMENTAL

Fecal Microbiota Transplant

Intervention Type: BIOLOGICAL

Double-encapsulated Fecal Microbiota Transplant Capsules

3 doses fecal microbiota transplant

This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.

Group Type: EXPERIMENTAL

Fecal Microbiota Transplant

Intervention Type: BIOLOGICAL

Double-encapsulated Fecal Microbiota Transplant Capsules

Interventions

Fecal Microbiota Transplant

Double-encapsulated Fecal Microbiota Transplant Capsules

Intervention Type: BIOLOGICAL

Other Intervention Names

FMT Capsule DE

Eligibility Criteria

Inclusion Criteria

• Current enrollment in the Wisconsin ADRC clinical core study (2011-0030), ADCP (26695, MCW IRB), or referred from clinic
• At least 45 years of age

• Abnormal memory function documented by neuropsychological testing
• Wisconsin ADRC (HS IRB# 2015-0030) Consensus Diagnosis Conference indicates probable AD diagnosis as per NINDS/ADRDA criteria for probable AD (for ADRC and ADCP participants only).

Exclusion Criteria

• Willing and able to comply with all study procedures for the duration of the study
• Able to provide signed and date informed consent form
• Participant is not pregnant, lactating or of childbearing potential (ie women must be two years post-menopausal or surgically sterile
• Males must agree to avoid impregnation of women during and for four weeks after completing study treatment through use of an acceptable method of contraception
• Able to take oral medications
• Able to take the test capsule successfully with no signs or symptoms of dysphagia

• Active or previous (within 6 months) participation in an Alzheimer's clinical intervention/trial
• Significant neurologic disease: Any significant neurologic disease, such as Parkinson's disease, stroke, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, subdural hematoma, multiple sclerosis, seizure disorder, or other significant deficits (other than Alzheimer's dementia)
• Alcohol/substance: history of alcohol/substance dependence since joining the cohort
• Psychiatric disorders: Untreated current axis 1 DSM-V disorder such as major untreated depression, current untreated bipolar 1 disorder, untreated schizophrenia spectrum disorders, or other conditions potentially affecting study adherence.
• Significant medical illness: any significant systemic illness or unstable medical condition occurring that could affect cognition (other than Alzheimer's). Examples include malignant cancer, chemotherapy, untreated thyroid disease, heart failure, or renal insufficiency.
• Illiterate, blind, or non-English speaking
• Known periodic antibiotic use (i.e. prior to dental appointments)

• Inability (e.g. dysphagia) or unwilling to swallow capsules - assessed using the Eating Assessment Tool (EAT-10) and bedside 3oz water swallow test administered by CRU nurse or study coordinator
• Active gastrointestinal infection at time of enrollment
• Known or suspected toxic megacolon and/or known small bowel ileus
• History of total colectomy or bariatric surgery
• Concurrent intensive induction chemotherapy, radiation therapy, or biological treatment for active malignancy
• Unable or unwilling to comply with protocol requirements
• Expected life expectancy < 6 months
• Previous FMT or microbiome-based products at any time excluding this study
• Patients with severe anaphylactic or anaphylactoid food allergy
• Solid organ transplant recipients ≤ 90 days post-transplant or on active treatment for rejection
• Immunocompromised/ at risk of CMV/EBV associated disease
• A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study
• Exclusionary factors affecting the microbiome:

• Use of systemic antibiotics (intravenous, intramuscular, or oral) in the previous 3 months
• Oral, intravenous, intramuscular, nasal or inhaled corticosteroids (except PRN use for allergies)
• Immune stimulating medications
• Methotrexate or immunosuppressive cytotoxic agents
• Large doses of commercial probiotics consumed (greater than or equal to 108 cfu or organisms per day). Includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component (ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply).
• Unstable dietary history during the previous month, which is defined as major changes in diet by eliminating or significantly increasing a major good group
• Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years
• Major bowel resection at any time
• Active uncontrolled gastrointestinal disorders or disease including: inflammatory bowel disease including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis; irritable bowel syndrome (moderate-severe); persistent, infectious gastroenteritis, colitis or gastritis; persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated), or chronic constipation

• Minimum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Wisconsin Partnership Program

OTHER

Sponsor Role: collaborator

University of Wisconsin, Madison

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Barbara Bendlin, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Wisconsin, Madison

Locations

University of Wisconsin - Madison

Madison, Wisconsin, United States

Countries

United States

References

Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB, Rey FE. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017 Oct 19;7(1):13537. doi: 10.1038/s41598-017-13601-y.

Reference Type: BACKGROUND

PMID: 29051531 (View on PubMed)

Other Identifiers

2018-0283

Identifier Type: OTHER

Identifier Source: secondary_id

A534255

Identifier Type: OTHER

Identifier Source: secondary_id

SMPH/MEDICINE/MEDICINE

Identifier Type: OTHER

Identifier Source: secondary_id

AMBITION

Identifier Type: -

Identifier Source: org_study_id